in I sale coincidence through be but we're driven by our earnings, first simply having Thank priority you, when of QX. quarter's to Meg. bit have positive Welcome the to to that Krystal this positive Biotech's that is a of earnings first-ever earnings be the call. run a EPS It's we clear call want
awareness Bullosa for the thank work on to community week. the We Epidermolysis outcomes entire importantly, More the having we're call with disease. improve hem tirelessly genetic to Dystrophic patients of this DEB
focused extends disease beyond know that as and and the the patients disease we're committed many helping our single every day, to challenges families far work goal that recognize patients comprehensively. possible. this we their We treat face to on continuing the remains as As the DEB skin, to
early our we're that with patients discuss proud cell say skin in of a and in like I'd quarter DEB into to the progress will efforts full those making. commercial that, the carcinoma first and later the I'm With of after initial this treating squamous glance, in extremely call. that the lesions We bulge the with eye pleased
to approved. Start demand continue XXX was into we And we VYJUVEK Forms patient see strong QX. as announced, QX finished since We with
plug, update from is as continue Our more an XX% on the from we'll continue estimate we're patients in identified conversion quarter now at full XX% of suffering were to dominant subsequent base stat Forms Start said, convert. post penetration That right form Start but patients about quarters Forms following to Forms to patients XXX received, at a even XX% launch. the Start of and from more X DEB. of the Of XX%, the
gene have sense will potentially we did. younger as XX% time period they were of more before, As our young dominant Forms of that ten of I've us as to of years of expand scripts mentioned for induction a as that than patient the patients because identified DEB months than estimate meaning longer to phase Start a of track adults, patients patients ten could of it patients. that induction One-third adults a than an from continue better We believe age age six old. overall years gives from of phase potentially consume the viral base longer
of which patients and as presently on conversion estimate move stock half surprising patients to quarters. is and excellence we by less higher interesting of patients Start physicians. centers with community into the from XX% or is bit written of the a maybe So patients, potentially balance XXX XX% the only were related scripts What be were from ten could Forms subsequent than years drug, dominant from that farms, DEB XX% of an XX% younger,
center from is not attributable of visit to to but excellence, Forms. at has a Start And the that patient this on flow KOLs rather it of So steady their them physically centers to: a some a been bolt one, baseband. initiating wanting prior
lot the of and time takes amount KOLs. that not of scheduling these of a excellence the can certain live given right do Now often a center busy a because schedule of to next be patients challenge
of Kells, have it Basabe eligible experience a patients open-label with with the been issue. patient closely received their study other insurance KOLs were the over the choosing patients the who study siler gated on reinvestment. Vivek XX% working our a in And are approach, a affairs is medical reimbursement, generally, for as of importance from prioritizing reseat to of Some commercial prior respect not extension or possible. most those as plan. them of platforms end how patients, we've the soon to these in did clinical any commercial XX% then on team wanting With QX these timing scored to KOL Most of getting educate with them of prescriptions as from with encountered patients have goes that no patients. are seeing already on put for base simply said, to reluctance patients writing their moderate on is and respect first, a That
plans press from release, As regional health terminations mentioned major the health national the plans. all company in has succeeded positive and to several commercial we coverage
becomes the insurance, insurance January XX% reimbursement, XX% permanent to government of we remaining available XXXX. are and presently remaining commercial So in eligible expect the for on eligible J-code the XX% be once
to homes. good of point, So reporting reimbursement all XXXX. patients in patient on forms overall, and staff will almost eligible early of as we expect and be become we a for At much as better some very drug opposed starts in patients transition to drug net this revenues a of patients to form place, to on is predictor intend access number
access, advisory VYJUVEK launch the start of and respect principle getting around Krystal's about centered and worked smooth, transitioning to tirelessly are on experience, home talked previously than and right local net state. convenient timely a half a in involved weekly We're them to of we is traveling that each families a treatment with about their at staying and it filled getting patients on with patient is color the ensure now on have to having Think center to pharmacy. on revenues. we conversion palliative more pension medication visit physician by for So script that.Definitely, a and the guiding at excellence and forms health who partnering to simply HCP steps apply to an time schedule. and the about
also almost home agree patient. who In payers with that the pledged we're addition, for working the all setting is
work experience time. unless a is patient line to and that of not start patient we the our a make a to clear sight reason, VYJUVEK ensure don't respective patients mind our for So we we have into access wait the long getting from that do foremost on reasonable accept we within
patients. patients experiences goal place the to Start weeks. learning drug yet, XXXX to to in from Forms Our have the on of And X expect of the X in on is we're access of of We're in most we'll by about convert end initial there but set year. the we some not
two it upon difficult achieving with that a filing. X schedule confident takes week So families or get below we us go to or really objective. weeks really many to and It's feel comfortable in because health to X
expect all this to we to the trend rate to in upcoming the at for So continue has XX%. and And dosing. patients' helped drug, potentially We Over currently go that been home. and dosed around tracks to adherence launch quarters. to has shall this continue patients has high. were doctors This want excellent update XX% definitely by of home about be been received September of end who which statistic
took So few the it following to drug negotiate home in health weeks and us channel, approval get in visits. May, reimbursement schedule the a
early patient paid did VYJUVEK get on first our not until So August.
net of revenue months X.X USD million number is full in the revenue approximately X QX. So
During government product attributable both full The and while only the continue revenue where negotiated two issued. and Start and quarter. attributable to net Forms be quarter, months being, is to in more reimbursement a is point patient a to or period policies commercial
a recess in both and So to smooth been pointing demand health access a high has coverage strong are good We relatively really home have we patients. visits see believe summarize, dominant to from patient we hands. and launch our compliance.
We forward. expect to going this momentum continue
the we're looking expand a second launch call the name marketing clinical approval commercial XXXX also we're and our of of a will VYJUVEK, the the and well EU to pipeline programs. our authorization shortly, to programs. launch, XXX await with the treated strength balance sheet, working in I U.S. financially speak over a are of support and after. Suma the and to half to number as turn provide in to global productive we patients USD patient our Suma of Beyond the towards we launched but our strong very on advance color on strategically to shall positioned pipeline, clinical close VYJUVEK launch and million program
